Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Hepatitis B Virus Core Antigen (HBcAg) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Hepatitis B Virus Core Antigen (HBcAg) Products under Development by Stage of Development | 7 | 1 |
| Hepatitis B Virus Core Antigen (HBcAg) Products under Development by Therapy Area | 8 | 1 |
| Hepatitis B Virus Core Antigen (HBcAg) Products under Development by Indication | 9 | 1 |
| Hepatitis B Virus Core Antigen (HBcAg) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Hepatitis B Virus Core Antigen (HBcAg) Products under Development by Companies | 12 | 2 |
| Hepatitis B Virus Core Antigen (HBcAg) Therapeutics Assessment | 14 | 4 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Route of Administration | 15 | 1 |
| Assessment by Molecule Type | 16 | 2 |
| Hepatitis B Virus Core Antigen (HBcAg) Companies Involved in Therapeutics Development | 18 | 5 |
| Abivax S.A. | 18 | 1 |
| F. Hoffmann-La Roche Ltd. | 19 | 1 |
| Gilead Sciences, Inc. | 20 | 1 |
| Transgene SA | 21 | 1 |
| VLP Biotech, Inc. | 22 | 1 |
| Hepatitis B Virus Core Antigen (HBcAg) Drug Profiles | 23 | 8 |
| ABX-203 Drug Profile | 23 | 1 |
| GS-4774 Drug Profile | 24 | 2 |
| hepatitis B vaccine Drug Profile | 26 | 1 |
| RG-7944 Drug Profile | 27 | 2 |
| TG-1050 Drug Profile | 29 | 2 |
| Hepatitis B Virus Core Antigen (HBcAg) Dormant Projects | 31 | 1 |
| Hepatitis B Virus Core Antigen (HBcAg) Featured News &Press Releases | 32 | 11 |
| Dec 08, 2015: ABX203 (HeberNasvac) Granted Cuban Marketing Authorization to Treat Chronic Hepatitis B | 32 | 1 |
| Nov 04, 2015: Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection | 33 | 1 |
| May 27, 2015: GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients | 33 | 1 |
| Apr 23, 2015: Transgene Presents New Data with TG1050, an Immunotherapy Being Developed to Treat Chronic Hepatitis B, at The International Liver Congress 2015 | 34 | 1 |
| Apr 21, 2015: Inovio Pharmaceuticals and Roche Initiate Clinical Trial for Inovio's DNA Immunotherapy to Treat Chronic Hepatitis B Infection | 34 | 1 |
| Feb 26, 2015: ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B | 35 | 1 |
| Jul 01, 2014: Transgene Announces Presentation of Data on TG1050 Immunotherapy against Chronic Hepatitis B | 36 | 1 |
| Nov 05, 2013: Transgene Announces Data on TG1050 Presented at Recent Medical and Scientific Conferences | 36 | 1 |
| Apr 29, 2013: Transgene Presents Positive Preclinical Data On TG1050 To Treat Chronic HBV At EASL 2013 | 37 | 1 |
| Apr 08, 2013: Transgene To Present New Data On TG1050 To Treat Chronic Hepatitis B At EASL 2013 Conference | 38 | 1 |
| Jan 28, 2013: GlobeImmune Initiates Phase Ia Clinical Trial Of GI-13020 In Healthy Volunteers | 38 | 1 |
| Nov 12, 2012: Inovio Pharma's Hepatitis B Vaccine Demonstrates Potential To Clear Hepatitis B Virus In Liver In Preclinical Study | 39 | 1 |
| Nov 12, 2012: Inovio Pharma's Therapeutic Hepatitis B Vaccine Killer T Cells Demonstrate Potential To Clear HBV In Liver | 39 | 1 |
| Apr 19, 2012: Transgene s New Therapeutic Vaccine Candidate to Treat Chronic Hepatitis B Reaches Preclinical Proof of Concept | 40 | 1 |
| Oct 10, 2011: Inovio Pharma And VGX International To Advance Therapeutic Hepatitis C And Hepatitis B Synthetic Vaccines Into Clinical Studies | 41 | 2 |
| Appendix | 43 | 2 |
| Methodology | 43 | 1 |
| Coverage | 43 | 1 |
| Secondary Research | 43 | 1 |
| Primary Research | 43 | 1 |
| Expert Panel Validation | 43 | 1 |
| Contact Us | 43 | 1 |
| Disclaimer | 44 | 1 |